prakash nallathamby (@prakashdn) 's Twitter Profile
prakash nallathamby

@prakashdn

Biomedical Engineer - Therapeutics to combat multidrug resistance.
Views are mine.

ID: 50706679

calendar_today25-06-2009 17:22:36

661 Tweet

234 Takipçi

494 Takip Edilen

Nature Reviews Drug Discovery (@natrevdrugdisc) 's Twitter Profile Photo

For readers interested in lipid nanoparticles for nucleic acid delivery, here's a perspective by Cullis and Feldner on the evolution of the field rdcu.be/eMpeO nature.com/articles/s4157…

For readers interested in lipid nanoparticles for nucleic acid delivery, here's a perspective by Cullis and Feldner on the evolution of the field 
rdcu.be/eMpeO
nature.com/articles/s4157…
good papers (@paperperday) 's Twitter Profile Photo

Rewiring microbial metabolism through post-translational switches "Post-translational regulatory tools-synthetic degradation tags, spatial regulation via subcellular compartmentalization, allosteric protein engineering for dynamic enzyme activity control" sciencedirect.com/science/articl…

Rewiring microbial metabolism through post-translational switches

"Post-translational regulatory tools-synthetic degradation tags, spatial regulation via subcellular compartmentalization, allosteric protein engineering for dynamic enzyme activity control"
sciencedirect.com/science/articl…
Biology+AI Daily (@biologyaidaily) 's Twitter Profile Photo

One Protein Is All You Need 1. A new method called Protein Test-Time Training (ProteinTTT) has been proposed to enhance the generalization of protein language models to individual proteins. This method enables self-supervised customization of models to one target protein at a

One Protein Is All You Need

1. A new method called Protein Test-Time Training (ProteinTTT) has been proposed to enhance the generalization of protein language models to individual proteins. This method enables self-supervised customization of models to one target protein at a
Nature Reviews Drug Discovery (@natrevdrugdisc) 's Twitter Profile Photo

For readers interested in new approach methodologies for assessing the safety of drug candidates, here's a Perspective from an EFPIA expert group rdcu.be/eMzJ3 nature.com/articles/s4157…

For readers interested in new approach methodologies for assessing the safety of drug candidates, here's a Perspective from an EFPIA expert group 
rdcu.be/eMzJ3
nature.com/articles/s4157…
nature (@nature) 's Twitter Profile Photo

Nature research paper: Bottom-up design of Ca2+ channels from defined selectivity filter geometry go.nature.com/3WV25A4

Elliot Hershberg (@elliothershberg) 's Twitter Profile Photo

Epic. Another big step toward universal binder design. Produced nanomolar binders for 6/9 targets with no known binders and low (<30%) sequence similarity to any structural complex in the PBD. The Boltz team is unreal. All open-source and in the hands of scientists around the

Nature Reviews Drug Discovery (@natrevdrugdisc) 's Twitter Profile Photo

For readers interested in the potential to target particular protein isoforms as a way to achieve greater drug specificity, here's a review rdcu.be/eNiHj nature.com/articles/s4157…

For readers interested in the potential to target particular protein isoforms as a way to achieve greater drug specificity, here's a review 
rdcu.be/eNiHj
nature.com/articles/s4157…
Rockefeller University (@rockefelleruniv) 's Twitter Profile Photo

In nature: Using AI and other cutting-edge techniques, the Klinge lab has captured the first near-continuous "molecular movie" of ribosome formation—revealing, frame by frame, how cells build the protein factories that make life possible. More here: rockefeller.edu/news/38513-maj…

Samuel Hume (@drsamuelbhume) 's Twitter Profile Photo

Ongoing Eli Lilly trials Particularly interesting are the major phase 3 trials for single, dual, and triple GLP1s in such a range of conditions Inflammatory bowel disease, lower back pain, psoriasis, hypertension, stress urinary incontinence, osteoarthritis, sleep apnea...

Ongoing Eli Lilly trials

Particularly interesting are the major phase 3 trials for single, dual, and triple GLP1s in such a range of conditions

Inflammatory bowel disease, lower back pain, psoriasis, hypertension, stress urinary incontinence, osteoarthritis, sleep apnea...
ICC (@icc) 's Twitter Profile Photo

A knock to remember! Jemimah Rodrigues' stunning hundred guides India into the #CWC25 final 👏🎉 She wins the aramco POTM award for her stellar performance 👌

A knock to remember!

Jemimah Rodrigues' stunning hundred guides India into the #CWC25 final 👏🎉

She wins the <a href="/aramco/">aramco</a> POTM award for her stellar performance 👌